Eyenovia’s Special Meeting: Support for Reverse Stock Split Grows
New York-based Eyenovia, Inc. (NASDAQ: EYEN) is making strides as it makes a push for a proposed reverse stock split. Recently, the distinguished proxy advisory firms, Institutional Shareholder Services Inc. (ISS) and Glass Lewis & Co., have thrown their endorsement behind this pivotal measure.
Details of the Proposed Reverse Stock Split
The upcoming Special Meeting of Stockholders is significant, as it’s not just about one proposal but several key points that could shape the future of the company. Eyenovia intends to adjust the ratio of its issued shares of common stock between 1:40 and 1:80, a move designed to help the company comply with the Nasdaq’s Minimum Bid Price Requirement.
Key Proposals for Consideration
During this important meeting, stockholders will deliberate on several proposals, among which the reverse stock split is the standout:
- Approval of Reverse Stock Split: The first proposal seeks approval for the adjustment of issued common stock shares.
- Omnibus Stock Incentive Plan Adjustment: Shareholders will also vote on amending an incentive plan to reserve an additional 350,000 shares, unaffected by the reverse split.
- Possible Issuance of Shares: There’s a proposal regarding the potential issuance of up to 73,029,273 shares upon exercising outstanding warrants.
- Meeting Adjournment Authorization: If quorum is established, stockholders may authorize an adjournment to solicit more proxies if necessary.
Company Leadership Reacts
Michael Rowe, Eyenovia's CEO, expressed optimism about the support from proxy firms. "We are pleased to see both ISS and Glass Lewis backing the proposed reverse stock split. If approved, this move allows us to meet Nasdaq's compliance standards, which is vital for our business continuity. We encourage stockholders to actively participate in the vote, as these measures are essential for our progress," stated Rowe.
Efforts Toward Compliance
Regaining compliance with Nasdaq rules isn’t just a bureaucratic formality; it significantly impacts Eyenovia’s visibility and stock liquidity. A strong market presence not only draws investor attention but also opens doors to capital needed for future developments.
Special Meeting Logistics
Mark your calendars, as the 2025 Special Meeting of Stockholders is set to be conducted virtually on January 21, 2025. Interested stockholders must pre-register by the end of January 20 to ensure their voice is heard during the meeting.
How to Prepare for the Meeting
Stockholders are encouraged to review the definitive proxy statement filed with the U.S. SEC for a comprehensive overview of the proposals at stake and implications for their investments. Knowledge is power, especially when movements in corporate governance impact shareholdings.
About Eyenovia, Inc.
Eyenovia, Inc. is an innovative player in the ophthalmic technology space, specializing in the development of its proprietary Optejet system. This platform aims to enhance the delivery of topical ophthalmic medications, targeting both everyday ocular lubrication needs and chronic front-of-the-eye conditions. With a firm commitment to elevating treatment protocols, Eyenovia continues to seek advancements in ease of use and patient compliance.
Frequently Asked Questions
What is the purpose of the reverse stock split proposed by Eyenovia?
The reverse stock split aims to help Eyenovia comply with Nasdaq's Minimum Bid Price Requirement, which is crucial for maintaining its exchange listing.
When is the Special Meeting of Stockholders taking place?
The Special Meeting is scheduled for January 21, 2025, and will be conducted virtually.
What proposals will be voted on during the meeting?
Stockholders will consider the reverse stock split, an amendment to the stock incentive plan, potential share issuance, and authorization for adjournment.
How can stockholders participate in the meeting?
Stockholders must pre-register by January 20, 2025, to attend the virtual meeting and cast their votes.
How does Eyenovia’s Optejet platform benefit patients?
The Optejet platform offers an advanced method for dispensing topical medications, enhancing safety, ease of use, and potentially improving treatment compliance for patients with eye conditions.
